RZLT Rezolute, Inc.
Price Chart
Executive Summary
Rezolute announced four presentations at the ENDO 2026 conference, including an oral presentation of previously reported Phase 3 sunRIZE results for ersodetug in congenital hyperinsulinism. The Phase 3 study failed to meet its primary or key secondary endpoints in December 2025, and the FDA has requested comprehensive data for independent evaluation. This press release is a routine scientific conference update with no new clinical data or material financial information.
Actionable Insight
This is a routine conference update with no new data — no immediate trading catalyst. Monitor for FDA's independent evaluation of the sunRIZE dataset, which could determine the regulatory path for ersodetug. The failed Phase 3 remains the key overhang; any positive FDA feedback would be a significant catalyst.
Key Facts
- Rezolute will present four presentations at ENDO 2026 (June 13-16, 2026) in Chicago.
- One oral presentation will highlight previously reported Phase 3 sunRIZE results for ersodetug in congenital hyperinsulinism.
- The Phase 3 sunRIZE study did not meet its primary or key secondary endpoints (announced December 2025).
- FDA encouraged Rezolute to submit comprehensive analysis datasets for independent evaluation.
- Three poster presentations cover natural history of congenital HI, compassionate use of ersodetug in tumor HI, and systematic review of outcomes.
- No new clinical data, financial results, or regulatory milestones are reported in this press release.
Financial Impact
No financial figures disclosed; the press release is a scientific conference update with no material financial impact.
Risk Factors
- Phase 3 sunRIZE study failed primary and key secondary endpoints — regulatory path for ersodetug is uncertain.
- FDA independent evaluation could result in a complete response letter or additional trial requirements.
- No revenue or near-term commercialization timeline — stock is binary on regulatory outcomes.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3306662 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 11, 2026
3d ago
|
Institutional Cluster
| $3.81 awaiting T+1 | awaiting T+1 | — | $4.00 (+4.99%) |
|
Jun 4, 2026
10d ago
|
Press Release
| $4.51 $4.25 | ▼ −5.76% | ▼ −3.17% | $4.00 (−11.31%) |
|
Jun 2, 2026
12d ago
|
8-K
| $4.00 $4.58 | ▲ +14.50% | ▲ +15.19% | $4.00 (0.00%) |
|
May 12, 2026
4w ago
|
8-K
| $3.33 $3.33 | · 0.00% | ▲ +0.00% | $4.00 (+20.12%) |
|
May 12, 2026
4w ago
|
Press Release
| $3.33 $3.33 | · 0.00% | ▼ −0.00% | $4.00 (−20.12%) |
|
May 1, 2026
6w ago
|
Press Release
| $3.30 $3.30 | · 0.00% | ▲ +0.34% | $4.00 (+21.21%) |
|
Apr 21, 2026
7w ago
|
Press Release
| $3.28 $3.33 | ▼ −1.52% | ▼ −0.51% | $4.00 (−21.95%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access